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Abstract 
Innovative methods and materials have been developed to overcome limitations associated 
with current drug delivery systems. Significant developments have led to the use of a variety 
of materials (as excipients) such as inorganic and metallic structures; marking a transition 
from conventional polymers. Inorganic materials, especially those possessing significant 
porosity, are emerging as good candidates for the delivery of a range of drugs (anti-biotics, 
anti-cancer and anti-inflammatories), providing several advantages in formulation and 
engineering (encapsulation of drug in amorphous form, controlled delivery and improved 
targeting).  This review focuses on key selected developments in porous drug delivery 
systems. The review provides a short broad overview of porous polymeric materials for drug 
delivery before focusing on porous inorganic materials (e.g. Santa Barbara Amorphous 
(SBA) and Mobil Composition of Matter (MCM)) and their utilisation in drug dosage form 
development.  Methods for their preparation and drug loading thereafter are detailed. Several 
examples of porous inorganic materials, drugs used and outcomes are discussed providing the 
reader with an understanding of advances in the field and realistic opportunities. 






Drug delivery is the approach of administering therapeutic agents (in various formulations) to 
attain desired therapeutic effect (s) (1,2). Over the years, drug delivery methods have 
improved and evolved significantly to enhance patient compliance, drug bioavailability, 
safety and therapeutic index (3). Advances in routes of administration also impact both drug 
efficacy and pharmacokinetics (4), and the oral route is the most popular and convenient for 
patients (5). However, there are some limitations including; dysphagia (inability to swallow), 
erratic absorption and drug degradation in the gastrointestinal tract (e.g. peptides and 
proteins) resulting in reduced bioavailability (4-6). Innovative methods have been developed 
to overcome such limitations. Size reduction is an advanced approach for the delivery of an 
accurate therapeutic dose, controlled drug release, targeted delivery, improved 
pharmacokinetics and to reduce adverse reactions (2,7). Moreover, several unorthodox 
strategies have been explored to utilise structures on the nano- and micro-meter scales that 
are promising candidates and emerging systems for drug delivery. These include 
microspheres (8,9),  dendrimers (10,11), nano-particles (12,13), nano-emulsions (14,15), 
nano-fibers (16,17), micelles (18), niosomes (19,20), liposomes (21,22) and proniosomes 
(23,24). 
This review focuses on selected developments in porous inorganic drug carriers. A short 
overview of organic materials is also provided before various aspects of inorganic materials 
(structure, synthesis, applications and toxicity) are discussed with selected findings 
summarised  in three tables. 
2. Materials used for drug delivery 
A broad range of natural and synthetic materials have been used as excipients (and device 
platforms) for several applications in drug delivery; such as polymers, lipids, surfactants, 
ceramics, inorganic and porous materials.  
Progression in polymer science has contributed significantly towards novel drug delivery 
technologies (25) for enhanced, sustained and controlled release (26,27). Polymers (natural 
and synthetic) are either biodegradable or non-biodegradable. They provide therapeutic 
benefits in which they can serve as bio-active agents or simply as carriers for molecules of 
interest (hydrophilic and hydrophobic). Ideally, they must be both biocompatible and 
biodegradable, which improves drug release kinetics and enables a systematic method for 
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their removal from the body (26). Natural polymers (e.g. collagen, alginate, chitosan and 
carrageenan) which are generally extracted from natural compounds have the advantage of 
being biocompatible and biodegradable. In contrast, synthetic polymers are synthesised as 
either biodegradable (e.g poly(glycolic acid) (PGA), poly(adipic acid), polyamino acids, 
poly(ε-caprolactone) (PCL) and polyphosphonates) or non-biodegradable (e.g. polyvinyl 
pyrrolidone, carboxymethyl cellulose, poly(methyl methacrylate) (25). The use of synthetic 
polymers for drug delivery system development provides distinct advantages over naturally 
occurring types, largely due to the ability to tailor their chemical and physical properties (e.g. 
chain structure, solubility, size and biodegradability) (28). 
Lipid based drug delivery systems work on the basis of improving hydrophobic drug 
solubility, absorption and bioavailability by encapsulation/solubilisation (6). These are 
available in different forms; such as drug in lipid solutions (e.g. halofantrine (29)), 
microemulsions (e.g. etodolac (30)), emulsions (e.g. bupivacaine (31)), liposomes (e.g. 
doxorubicin (32)) and solid-lipid nanoparticles (e.g. minoxidil (33)). 
Surfactants have also contributed towards the development of advanced drug delivery 
systems (34). They are used in all pharmaceutical disperse systems (e.g. emulsions, 
suspensions, foams, gels and composites) (35). Moreover, they can be used as drug 
vehicles/carriers or targeting systems (36) and in topical formulations to enhance drug 
penetration across epithelial barriers (37,38). There are several types of surfactants; anionic 
(e.g. carboxylates and sodium lauryl sulphate), cationic (e.g. cetyltrimethyl ammonium 
bromide and benzalkonium chloride), non-ionic (e.g. Tween® 80 and Span® 80) and 
zwitterionic (e.g. sulphobetaine and dodecyl betaine) (37). 
Ceramic nano-powders provide an alternative approach for drug delivery. Ceramics are non-
immunogenic materials which are compatible with biological tissues, excipient chemicals and 
drugs (39). Bioceramics (e.g. silica-based glasses and calcium phosphates) have been utilised 
for local drug delivery; such as treating osteoporotic fractures, large bone defects, bone 
tumours and bone infections (40).  
Nanoparicles prepared from oxides of silver, gold, silica, titanium, iron, copper and zinc have 
potential use in several biomedical applications including drug delivery, cellular and 
bimolecular labelling, cancer targeting and biosensing  (41). These nanoparticles are capable 
of delivering multi-functional properties e.g. antibody functionalised gold has been shown to 
provide both selective imaging and photo-thermal apoptosis of cancerous cells (42).  
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Among the various carrier systems, porous materials are evolving as an innovative class of 
host/guest systems (43). Their porous structure permits encapsulation of a variety of active 
molecules (44) and have also shown great promise in many miscellaneous medical fields. 
Furthermore, as is the case with synthetic polymers; porous materials can be designed as 
fibres, micro- and nanoparticles, coatings and monoliths (44). 
3. Porous materials 
Porous materials have been used as controlled drug delivery carrier systems with optimistic 
properties, such as well-organised stable architectures, modifiable and uniform pore sizes and 
large surface areas (43-45). For inorganic porous materials, the porous state is classified 
according to the pore size boundary i.e. macroporous (pore size >50 nm), mesoporous (pore 
diameter 2-50 nm), and microporous (pore diameter <2 nm) (44). A variety of polymeric and 
inorganic porous carriers are widely available and extensively used in different types of 
biomedical and pharmaceutical applications such as active loaded tissue engineering 
construct, oral, topical and injectable drug delivery. 
3.1 Porous polymeric carriers  
Porous polymeric carriers are available in different morphologies i.e. microspheres, porous 
fibres, porous microneedles, as well as hydrogel systems. They are utilised for various 
pharmaceutical applications.  Porous polymeric microspheres with interconnected pores and 
large surface areas have been used as carriers for several therapeutic drugs, vaccines and 
genes (46,47). These particles have been engineered/synthesised from a variety of synthetic 
polymers (i.e. poly(lactic-co-glycolic acid) (PLGA) (46,47), poly lactic acid (PLA) (48,49), 
poly(methyl methacrylate) (50), poly-(methyl ethyl cyanoacrylate)(51), polyacrylamide (52) 
and Eudragit (53)). In addition, several natural polymers (such as; chitosan (54), polysucrose 
(55) and alginate (56)) have also been used for porous particle synthesis. 
As for their applications, porous polymeric microspheres have been explored for pulmonary, 
tissue engineering (as scaffolds), topical and oral delivery systems (e.g. microsponges). Large 
porous microspheres are considered as optimal drug carriers for pulmonary delivery (57). 
Their porous structure and large size can achieve deep lung deposition and therefore enhance 
drug delivery (58). Furthermore, porous particles with diameters greater than 5 µm in 
diameter and possessing mass densities less than 0.4 g/cm3 were inhaled deeply into the lungs 
and bypassed clearance mechanisms (59).  
5 
 
Porous biodegradable polymeric microspheres have been utilised as scaffolds for tissue 
engineering (60) with highly open inter-connecting porous microspheres ideal for cell 
delivery via impregnation. In this instance, the highly porous structure is essential to attain 
adequate cell seeding density and to facilitate oxygen and nutrient transportation across 
selected cells to promote their growth and proliferation (61). 
Microsponges are porous polymeric microspheres, and have been used for topical and oral 
drug delivery (62). They have been developed to enhance encapsulated drug stability against 
environmental and physical degradation (62,63). Also, microsponges can be used to improve 
the safety profile for various drugs and their efficacy (63). For instance, microsponges used in 
topical drug delivery can entrap topical ingredients (e.g. sunscreens, emollients, essential oils, 
fragrances and topical anti-inflammatory agents) and control their release onto skins surface 
(62) by gradually releasing the entrapped active to avoid its accumulation within the dermis 
and epidermis (64). For oral dosage form applications; entrapping poorly water soluble drugs 
in microsponge pores is one way to enhance their solubility (63,64) and to provide controlled 
release mechanisms to the lower gastric intestinal tract (63). 
Fibrous matrices (with interstitial porous features) offer large surface areas. These have been 
employed in several areas of tissue engineering and drug delivery (encapsulation and 
controlled drug release systems) (65-67). Various biodegradable (e.g. PCL (65), poly (L-
lactic acid) (PLLA) (66), PLGA (68)) and non-biodegradable (e.g. polystyrene (69)) 
polymers has been used.   
Porous microneedle arrays have been developed with potential applications in drug and 
vaccine delivery (70). This approach is valuable for applications requiring large surface areas, 
such as the insertion of microneedles into the skin to serve as tissue engineering scaffolds or 
biosensors. Microneedles may disengage from their substrate and remain embedded in the 
tissue for controlled drug delivery (71). Utilising microneedles from biodegradable polymers 
(e.g. PLA (71)) which degrade safely at the site of insertion is advantageous (70). Porous 
microneedles are naturally weaker than solid microneedles, and this may hinder their ability 
to penetrate the skin (70,71). Therefore, this approach still requires further exploration in 
order to deliver ideal platforms for dermal delivery (70). 
Hydrogels are cross-linked networks of water insoluble polymers (e.g. chitosan (72), 
poly(acrylic acid) (73) and alginate (74)) which are able to swell significantly in aqueous 
media (75). They are classified according to their network structure (porous to nonporous); 
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microporous, macroporous and superporous hydrogels (75). The network structure of porous 
hydrogels allows entrapment of drugs into their matrix (76). They are utilised as drug carriers 
with the ability to release the entrapped drug in a sustained profile (77). The release rate of 
the entrapped drug can be controlled by the pore size, the polymer biodegradability and the 
affinity of the drug to the polymer (78). Superporous hydrogels contain large quantities of 
interconnected and open pores within their network. Their highly porous structure is very 
useful for a range of novel drug delivery approaches, such as intestinal delivery of 
therapeutics and gastric retention (79). 
The aforementioned porous carriers are usually produced using biodegradable/non-
biodegradable polymers. Natural polymers are mostly biodegradable and provide high 
biocompatibility (25,28).  For instance, gelatine, chitosan, collagen and dextran are natural, 
biodegradable, biocompatible, nontoxic and non-immunogenic. While, sodium alginate is an 
example of a naturally occurring polymer, it does not undergo degradation via mammalian 
enzymatic action (28). Biodegradable polymers are preferred as they degrade in vivo to non-
toxic monomers (25). For example, PLA degrades to form lactic acid which is then 
metabolized through the Krebs cycle and excreted as carbon dioxide and water, mostly 
through respiration. PGA is another biodegradable polymer which degrades to glycolic acid; 
which is later excreted in urine (80). Most biodegradable polymers (e.g. PCL, PLA, PGA and 
PLGA) have proven to be biocompatible and nontoxic (80,81). However, the 
biocompatibilities of some polymers (e.g. PGA and PLA) maybe compromised when used in 
certain orthopaedic applications. They may release small fragments during their degradation 
stimulating foreign inflammatory reactions (80,81). These small fragments are finally 
phagocytised by multinucleated giant cells and macrophages (80). Some polymers produce 
acidic degradation products (e.g. PLA, PGA and PLGA) which affect cell integrity in their 
microenvironment by lowering the surrounding pH (82). Poly (methyl cyanoacrylates) is 
another biodegradable polymer but its degradation products (cyanoacetic acid and 
formaldehyde) are toxic (28).  
The elimination of non-biodegradable polymers is highly dependent on their molecular 
weight. Large non-biodegradable polymers may persist within tissue after cellular death or be 
eliminated through renal glomerular filtration if their molecular weight is lower than the renal 
excretion threshold (83,84). However, accumulation is a potential problem for all non-
biodegradable polymers. Even if the molecular weight of the polymer is below the renal 
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excretion threshold, some quantities of polymer (tail end of the molecular chain distribution) 
will still possess a higher molecular weight (84). 
3.2 Mesoporous inorganic porous carriers 
Inorganic porous materials are promising carriers for various types of drugs, genes and 
proteins. Their porous structure is beneficial to attain a controlled, sustained or pulsatile 
release in drug delivery applications. The diffusion rate of entrapped drug, gene or protein 
can be controlled by the materials porous and hydrophilic characteristics. Moreover, porous 
inorganic materials demonstrate high mechanical and chemical stability under a range of 
physiological conditions (44). They are classified into three classes according to their pore 
size; microporous inorganic materials (e.g. zeolites molecular sieves), mesoporous inorganic 
materials (e.g. MS and mesoporous metal oxides) and macroporous inorganic materials (e.g. 
macroporous aluminophosphate) (85). A transmission electron micrograph of mesoporous 
silica is shown in Figure 1. 
The term meso means “in between”, and is used by International Union of Pure and Applied 
Chemistry (IUPAC) to describe porous materials having pore size between the micropore and 
macropore range (2-50 nm). IUPAC classify mesoporous materials according to the nature of 
the materials network; ordered or disordered materials (86). Mesoporous materials are 
excellent matrices for controlled drug delivery and in recent times greater research efforts 
have been dedicated to develop various types of mesoporous materials with variable porous 
structure and functionality (87,88).  
The attractive features of these materials include their stability, well-defined surface 
properties, high pore volume, narrow pore diameter distribution and high surface area. These 
features allow the entrapment of drugs, proteins and other biogenic molecules and release 
them in a more predictable and reproducible pattern (87-90). Moreover, the size of their pores 
can be tailored from 1.5 to several tens of nanometres allowing their matrices to encapsulate a 
range of molecules (87). A variety of mesoporous materials have been utilised as substrates 
for drug delivery; such as mesoporous silica-based materials (91-97), carbon (98,99), zirconia 
(100), alumina (101,102), titanium oxide (103) and composites (104,105). Ordered 
mesoporous silica-based materials have drawn great research focus in the last decade because 
of their evolving applications in drug delivery and various other biomedical applications  
(97,106,107). They are made of SiO4 tetrahedra and exhibit ordered arrangements of pores 
(channels and voids) with different geometries. The pore size and geometry of these materials 
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can be tuned using several synthetic techniques (108). In 1992, family of silicate and alumina 
silicate ordered mesoporous materials called M41S was synthesised using liquid crystal 
templating (109,110). This family includes different members with different geometries. For 
example, MCM 41 (Mobil Composition of Matter 41) has arrays of two-dimensional 
cylinderical pores (2-5 nm) in a hexagonal arrangement, MCM-48 exhibits cubic three-
dimensional structure with unique bi-continuous channels (2-5 nm) and MCM-50 has a 
laminar structure (89,111). In 1998, Zhao and co-workers synthesised ordered mesoporous 
silica (MS) (20−300 Å) using non-ionic triblock copolymers. This type of mesoporous 
material is called SBA (Santa Barbara Amorphous) and the most representative members of 
this family are hexagonally ordered MS (SBA-15) and cubic MS (SBA-16) (112). SBA-15 
and SBA-16 have thicker walls and larger pore sizes compared to MCM-X type silica’s 
(113). MCM-41 and SBA-15 are presumably the most studied ordered MS materials (97). 
Other types of MS have been synthesised such as MSU (Michigan State University) (114), 
TUD (Technische Universiteit Delft) (115) and FSM (Folded-Sheet Mesoporous Material) 
(116) and MPS (synthesized mesoporous silica) (117) by using various synthetic techniques. 
Much work has been carried out applying synthetic mesoporous silica-based materials as 
controlled (90,118), targeted (106,107) and responsive (119) drug delivery systems. This is 
owing to their high thermal and chemical stability, biocompatibility, large surface areas and 
good compatibilities with other materials (89). In addition, these systems have the advantage 
of improving the utilisation of poorly soluble drugs. This is related to the interactions 
between the organic functional groups of the drug with germinal and single silanol groups 
available in the pore walls of mesoporous materials (120). Both small and large drug 
molecules have been encapsulated within mesoporous materials via solvent impregnation 
(89). The mechanism of drug release from such matrices is largely diffusion controlled and 
depends on many parameters such as chemical composition of their surface, pore size, pore 
connectivity, drug loading method, drug physicochemical properties and hydrophilicity of the 
platform (91,97,121). 
The release kinetics of drug from their matrices can be controlled by modifying the pore size 
(118), pore geometry (122), drug loading method (123) and surface functionalisation (90). 
Vallet-Regi et al, developed two types of MCM-41’s with different pore sizes using 
ibuprofen (model drug) with drug loading weight percent ratio of 30% (drug/MCM-41). 
Ibuprofen release (under static conditions) exhibited varying release profiles depending on 
the method of ibuprofen charging and not the pore size (123). Another work conducted by the 
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same group demonstrated release profiles of ibuprofen (under stirring conditions) were highly 
influenced by the pore size of MCM 41. The release rate of ibuprofen decreased as the pore 
size was reduced. Thus controlled drug delivery can be modulated by careful selection of 
mesoporous material pore size (118). 
MS pores can be tailored to various geometries and sizes. Pore size has a significant effect on 
drug loading and release rate. There are several architectures of mesoporous materials (such 
as those possessed by MCM-41, MCM-48 and SBA-15) that have an influence on the 
diffusion rate and the route of drug loading into the material. Mesoporous materials with 
short two-dimensional hexagonal pore  can also be characterised by direct diffusion of loaded 
drug into the release medium. While in three-dimensional cubic pore channels the loaded 
drug will require more time for the same quantity to diffuse due to longer non-linear pore 
channels (124). The release kinetics of drug molecules from silica matrix can be modified by 
functionalising its surface (silica) with different chemical moieties (89,125). For example, 
SBA-15 silica functionalised with amine groups was investigated as controlled drug delivery 
matrices for ibuprofen and bovine serum albumin (BSA, as model drugs). The time to 
functionalise the SBA-15 (post-synthesis or during one-pot synthesis, detailed later) was 
found to affect the adsorption capacity and release behaviour of both drugs. The release 
profiles of ibuprofen and BSA from SBA-15 were more effectively controlled by 
functionalising SBA-15 via post-synthesis (using ibuprofen) and using one-pot synthesis (for 
BSA). In addition, release profiles were highly dependent on different surface properties of 
SBA-15 materials (90).  
MS have been extensively utilised as MSN (107), MS-microspheres (126), MS-fibres (127) 
and MS-beads (128) or simply by inclusion/adsorption of therapeutic drug in the silica matrix 
(120). These drug delivery systems have shown promise as useful candidates for oral, topical 
or injectable drug carrier systems. 
For oral drug delivery, ordered silica-based mesoporous materials (e.g. MCM-41 and SBA-
15) have been used to design fast onset therapeutic effect formulations (120), to increase the 
dissolution rate of poorly soluble drugs (129) and to enhance drug bioavailability (97). The 
dissolution improvement associated with the utilisation of MS can be established by changing 
the solid state property of the entrapped drug from the crystalline to amorphous form. This in 
turn increases drug absorption from the intestine and consequently results in enhanced 
bioavailability (122). For instance, the inclusion of the hydrophobic drug ‘Itraconazole’ into 
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ordered MS accelerated its release and significantly enhanced its systemic bioavailability 
(97,130). The oral delivery of ibuprofen loaded into MS materials (SBA-15, MCM-41, and 
TUD-1) has shown to reduce the dependency of drug dissolution profile on the pH of the in 
vitro assessment medium. Thus at acidic pH, ibuprofen release demonstrated a significant 
improvement when using mesoporous silica, which in turn enhanced the drugs bioavailability 
(122). Furthermore, MSN has been developed as an oral drug delivery system, where the oral 
absorption of telmisartan was improved significantly via greater permeability and a reduction 
in drug efflux (131).  
With regards to topical delivery, silica nanoparticles are widely utilised for cosmetics and 
dermal therapies such as antioxidants, UV ray filters and antifungals (132). Flavonoids (e.g. 
quercetin (133) and rutin (134)) are used in topical cosmetic products to offer protective 
effects against photo-degradation because of their antioxidant and radical scavenging 
properties. However, their use is limited due to their low physicochemical stability (132). 
Encapsulation of quercetin in octyl-functionalised MCM-41 has also shown to improve its 
stability and performance without undermining its antioxidant properties (133). In another 
study, rutin (the glycoside of quercetin) was loaded into aminopropyl-functionalised MCM-
41 (NH2-MCM-41) maintaining the chemicals antioxidant property whilst also increasing the 
metal-chelating activity (134).  Trolox is another antioxidant that has been loaded into MCM-
41 clearly demonstrating improvements to photostability, while maintaining its radical 
scavenging property; which was demonstrated through slow diffusion from MCM-41 pores 
(135). In addition, MS has been used to entrap UV ray filters (e.g. benzophenone-3 (136), 
octal methoxycinnamate (137)). It was found that encapsulation of octal methoxycinnamate 
in the MS matrix (MCX-MS) was ~65 wt. % of MCX-MS and increased its SPF value by 
57% (137).  
A topical powder of econazole nitrate (an antifungal agent loaded into MCM-41) also 
demonstrated enhanced drug dissolution rate with high antifungal activity. In addition, the 
adsorption capacity of MCM-41 further assisted in the treatment of fungal infections by 
reducing moisture availability (found between folds in skin) which is usually ideal for fungal 
growth (138). 
With respect to intravenous drug delivery, MSNs have been explored for the delivery of 
anticancer drugs (12,119,139) and genes (140). Numerous anticancer drugs have low aqueous 
solubility and therefore cannot be administered intravenously thus MSNs have been deployed 
11 
 
as carrier systems to increase their solubility (12). Moreover, MSNs are able to increase the 
accumulation of anticancer drugs at the tumor site, thus improving their efficiency (139). 
MSN’s can be used intravenously for intracellular delivery of drug, especially where the 
entrapped drug is inside pores (not on the surface) and is released once in intracellular 
compartments (106). Inflammed tissue and tumors are more acidic than blood and normal 
tissue, and pH responsive drug delivery systems based on MSN have been developed for site 
targeted controlled release   (124,141,142).  
3.3 Synthesis of mesoporous silica 
 
 The basic synthesis of MS particles involves the addition of silica into a surfactant template 
solution which induces a reaction between the incorporated materials. The second step 
involves aging, filtration and calcination to obtain MS particles (143). Amongst these, the 
most employed templating technique for ordered MS synthesis is via liquid crystal 
mechanism (110,112,114,144). Here, liquid crystal structures (within the selected surfactant 
micellar solution as ordered arrays with different geometries i.e. cubic, hexagonal, or 
lamellar) serve as organic templates for the formation of silica mesoporous materials. The 
inorganic silicate precursor in the reaction mixture condenses around these arrays and forms 
silica walls reflecting their geometry. This is followed by removal of the templete via 
calcination, leaving the materials with a well-ordered mesoporous structure (110,114).  
In this regard, the role of template used in the preparation of MS (and applied temperature) is 
crucial as they are directly linked to MS pore size, where the temperature has a positive 
correlation with pore capacity.  Amphiphilic molecules are used for the synthesis of MSNs 
and they serve as a template to dictate the internal shape. In general, different types of 
templates are used in the synthesis of mesoporous materials such as  ionic surfactant (e.g. 
quaternary ammonium surfactants (92,110)),  non-ionic block copolymers (e.g. Pluronic 
(112)) and organic non-surfactant template (e.g. triethanolamine (115)). (ADDED) 
The calcination step in MS synthesis plays a critical role in determining drug delivery 
potential and biocompatibility because surfactant elimination is known to impede the porous 
silica network. For instance, calcined silica has exhibited a greater opened silica network 
compared to non-calcined samples. In addition, non-calcined silica is known to show greater 
quantities of silanol groups compared to their calcined counterparts (145). Table 1 shows 




3.4 Biodegradation and elimination of mesoporous silica 
 
Various biodegradability studies have indicated that functionalised and non-functionalised 
MS can be biodegraded in simulated body fluids and human cells (146-149). Degradation rate 
is significantly influenced by the surface area and initial concentration of mesoporous silica. 
Functionalisation of MS also influences the rate of degradation, for instance; 
functionalisation of MS with phenyl groups increased the degradation rate while 
functionalisation of MS with PEG resulted in slower kinetics (147). 
Hollow MSNs (HMSNs), a specific type of MS particle system, was shown to degrade inside 
human cells. Zhai et al, for the first time investigated the ability of HMSNs to degrade inside 
human umbilical vein endothelial cells. It was found that HMSNs degrade in the cytoplasm 
and lysosomes through two steps. The first degradation step occurs in both the cytoplasm and 
lysosome. The second is restricted to the lysosome. The degradation rate of HMSNs in cells 
was found to be fast in the first two days followed by slower rates in the following 48 hours. 
Furthermore, by-products of degradation were excreted into the culture medium (149). 
Another study performed by Chen et al demonstrated Stöber MSN (uniform spherical 
colloidal silica particles; synthesised by hydrolysis and condensation of tetraethoxysilan), 
almost degrade completely in SBF and human embryo kidney cells. This indicates such 
materials are promising canddiates for biomedical (drug delivery) applications (150). 
In relation to the elimination of MS particles, nearly 100% of injected silica nanoparticles 
were reported to be effectively removed post in vivo administration through hepatobiliary 
clearance, without inducing any hepatic toxicity (151). However, in vivo bio-distribution and 
urinary excretion studies of spherical MSNs found particles mainly distributed in the liver 
and spleen, with lower quantities also evident in the lung, kidney and heart. PEGylated MSNs 
were found to have a lower excretion in urine without causing any toxicity effect after one 
month of monitoring   (152). 
 
3.5 MS based materials in drug delivery 
 
MS based materials have been developed successfully for potential to deliver a host of drug 
types (e.g. anticancer, anti-inflammatory and antibiotics). Also, they serve as promising 
excipients and carriers for emerging biomedical and therapeutic applications such as tissue 
engineering and gene delivery, while their potential in co-delivery has also been explored. 
Table 2 shows selected drug delivery studies involving mesoporous inorganic materials. 
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Conventional chemotherapy has various drawbacks such as the inability of providing 
required drug concentrations at the tumor site, intolerable cytotoxicity and development of 
multi drug resistance. Moreover, ~40–60% of anticancer drugs have low bioavailability 
because of their poor solubility, high first pass metabolism, poor permeability through 
biological membranes and rapid clearance (106). Several research studies have been carried 
out in order to develop nano-carriers and tissue targeting systems that are able to overcome 
such medical barriers which retard the therapeutic effect of anticancer drugs   
(12,106,139,153,154). MS based materials are emerging as valuable carrier systems for the 
efficient treatment of cancer which is underpinned by multi-disciplinary research arising from 
complex materials, their physical properties and biological interactions (107). Studies have 
shown MS nano-carriers to enable suppressing effect cancerous tissue, whilst providing an 
effective dose, rapid excretion and reduced toxicity of loaded anticancer drug (139). The 
ability to control their pore size provides flexibility and tailored routes for drug encapsulation 
(153). Additionally, MSNs are capable of enhancing dissolution of poorly soluble anticancer 
drugs, thus increasing their bioavailability and efficiency (12,154). Silica based materials 
have been used for achieving intracellular targeted delivery of anticancer drugs which remain 
encapsulated within tunable pores; inhibiting premature release and degradation of drug in 
route to target tissues (106,139). They are promising for specific cell targeting as they can be 
covalently modified with targeting ligands (153). For instance, functionalisation of MSNs 
external surface with cancer specific ligands (e.g. antibodies and folic acid) allows selective 
targeting of nanoparticles to cancerous cells. These ligands can selectively bind to receptors 
that are extensively expressed on effected cell surface thus enhancing cellular uptake of 
anticancer drug (107,139). For example, folic acid was used as a ligand to target folate 
receptors which are overexpressed in various cancers (e.g. lung, colorectal, endometrial, 
breast, ovarian and renal cell carcinoma). Thus using folic acid as a targeting ligand enhances 
the uptake of anticancer drug within these cell types (107,155) and MS based materials have 
already been used successfully to encapsulate doxorubicin (153), camptothecin (12), 
paclitaxel (154) and methotrexate (155). Also several attempts have been made to overcome 
multi-drug resistance displayed by cancerous cells and to enhance chemotherapeutic 
efficiency via co-delivery of siRNA with anticancer actives  (156-158).  
MS materials have been effectively developed as carriers for several anti-inflammatory drugs 
(e.g. ibuprofen (90,118,122,123), piroxicam (120), sulfasalazine (141) and naproxen (159)). 
MSs were used to enhance the dissolution properties of anti-inflammatory drugs (120,122), to 
provide controlled release (118,123) and to target their release at the preferred site of action 
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(141).  For instance, the entrapment of piroxicam (a poor water soluble drug) (~%14) into 
MCM-41 mesoporous silicate (characterised by a large surface area and the presence of pores 
with diameters larger than the piroxicam molecular size. was shown to enhance piroxicam’s 
dissolution rate considerably and attained a rapid analgesic onset that was comparable to the 
analgesic effect of the marketed product Brexin® (120). Also, the use of MS as a carrier for 
ibuprofen was found to improve the drugs dissolution rate at low pH conditions (122). 
Controlling the delivery rate of ibuprofen entrapped in silica matrices was also investigated 
by functionalising the pore wall (90,96) and modifying the pore size (118). A slow release 
formulation of ibuprofen was obtained by loading ibuprofen into functionalised micron-sized 
MCM-41 spheres, which demonstrated a unique sustained release rate compared to 
irregularly shaped drug carriers (96). 
  
A pH targeted, responsive system for the delivery of sulfasalazine (anti-inflammatory 
prodrug) to colonic tissues was designed by functionalising MSNs with trimethylammonium. 
This novel system achieved minimal sulfasalazine release under acidic pH (stomach) and 
maximum release rate at neutral pH (colon). Therefore, the formulation offered targeted 
delivery of the prodrug to the colon, protecting it from degradation in the stomach and 
reducing its side effects (141). 
Several antibacterial agents have also been loaded into mesoporous silica, such as 
levofloxacin (145), vancomycin (160), gentamicin (95), amoxicillin (161) and erythromycin 
(162). MS has been used as a matrix for the incorporation of levofloxacin by both 
impregnation and surfactant-assisted drug loading methods. The antibacterial effect of this 
formulation was tested against Escherichia coli. Both drug loading methods resulted in 
matrices exhibiting similar levofloxacin release profiles (in vitro); displaying an initial fast 
release within the first ten hours followed by sustained release up to the end of the test period 
(350 hours). The lasting antibacterial activity of both systems indicated the suitability for 
local administration for the treatment of bone infections and osteomyelitis (145). 
Vancomycin was also loaded into sol-gel silica microspheres to design a sustained release 
formulation for the treatment of osteomyelitis. Optimization of the synthetic parameters 
achieved varied controlled release kinetics of vancomycin enabling selection of the desired 
therapeutic profile (160). Hexagonally ordered mesoporous SBA-15 were used to incorporate 
amoxicillin (161) and gentamicin (95) with controlled delivery properties. Two types of 
‘SBA-15’ were used for each drug: calcined powder and disk conformation. In vitro 
controlled release of amoxicillin was achieved by using SBA-15 as disks while the release 
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rate was faster when deploying SBA-15 calcined powder platform. In vitro controlled release 
of amoxicillin from SBA-15 (disk) system was comparable to traditional administration 
forms of amoxicillin formulations (such as suspension, tablets and capsules) (161). With 
regard to gentamicin, no significant difference between disk and calcined powder was 
detected for in vitro release study. Release profiles of both forms showed a high initial burst 
release (~60%) followed by a sustained release phase. When compared with traditional 
gentamicin dosage forms (e.g. injection, cream, suspension and ointment), the dissolution of 
SBA-15-gentamicin system was instantaneous (95). Amoxicillin remains the choice of 
treatment for infections such as bronchitis, pneumonia, and those related to the ear, nose, 
skin, and urinary tract. Gentamicin is used to treat infections caused by staphylococcus or 
resistant staphylococcus. Controlled delivery of amoxicillin and gentamicin in SBA-15 
material exhibited advantages when compared to conventional dosage forms where antibiotic 
dissolution is fast and immediate. These systems help by reducing the frequency of 
administration although the desired dose of antibiotic is achieved in controlled fashion 
(95,161). Ordered cubic three dimensional MS materials have been employed as carriers for 
the delivery of erythromycin. The release of erythromycin was controlled by modifying the 
pore size and functionalising the surface of mesoporous silica. A slow release was obtained 
as the pore size of the silica reduced. Also, functionalisation of silica surface decreased the 
release rate by a factor of ~six (162).  
 
MS materials have also been applied in tissue engineering research as they are promising 
bioactive materials (163). The bioactivity of silica materials, when in contact with 
physiological fluids, is attributed to the presence of silanol groups on their walls. Here, 
silanol groups are capable of forming interfacial bonds with tissues through carbonated 
apatite formation (163,164). Both pores (165) and silanol groups (166) act as nucleation sites 
for apatite layer formation. The silanol group concentration at the surface has a crucial effect 
on the bioactivity of materials. Moreover, the presence of mesoporous larger than 2 nm in the 
silica matrix not only enhances the formation of the carbonated apatite layer; but also 
increases tissue oxygenation (163). Also, such pores act as nutrient depots for cells by 
adsorbing growth factors and biomolecules thus promoting cell proliferation (167). 
Investigations into the bioactivity of MCM-41, MCM-48 and SBA-15 have elucidated that 
SBA-15 and MCM-48 are bioactive materials while MCM-41 is not. This can be explained 
due to the higher surface silanol concentration exhibited by MCM-48 and SBA-15 compared 
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to MCM-41 (163). Although, MCM-41 does not exhibit bioactivity, surface modification of 
MCM-41 is a route to induce bioactive behaviour (165). 
 
Silica based mesoporous materials have been investigated as scaffolds in reconstruction of 
hard tissue such as tooth and bone due to their bioactivity, biocompatibility, structure and 
textural properties (166). Furthermore, combining bioactivity and controlled drug release 
properties can be achieved by entrapping therapeutic drugs within meso-pores of silica based 
materials. This promising combination may result in a significant enhancement on their 
performance as biological scaffolds (163,168). MS based scaffolds used for bone tissue 
engineering have been prepared as different types of morphologies such as spheres (169), 
nanofibres (169) and nanoparticles (170). 
 
Gene delivery is rapidly emerging as an important treatment for genetically induced diseases; 
such as cancer, sickle-cell anemia and hepatitis C (171,172). Gene carriers must be on the 
nano-scale to function efficiently for gene transfection because large particles are problematic 
for uptake by mammalian cells (173). Various nano-scaled carriers such as polymers, lipids 
and inorganic nanoparticles have been used extensively to improve the cellular delivery of 
large range of nucleic acid agents (171). Among these carriers, MSNs have shown great 
potential for gene delivery (171,174) largely due to their small size permitting endocytosis 
into cells.  They allow stable delivery of DNA directly in to the cytoplasm and also the 
nucleus for transcription (140). Furthermore, MSNs also protect encapsulated genes from 
enzymatic action such as degradation (171,175). Surface modification of MSNs is an 
additional aspect being explored in the formulation of porous drug delivery systems. The use 
of various moieties to serve functions outside of targeting (e.g. optimization of nucleic acid 
adsorption and release characteristics) has also been explored (174,175). For example, 
functionalisation of MSNs with histidine has demonstrated enhanced gene transfection 
efficiency (176) and when using degradable poly (2-dimethylaminoethyl acrylate) controlled 
release of siRNA in to cells is achievable (174). However, the loading of large bimolecular 
genes into meso-pores of MSN is not straightforward, and many studies have shown DNA 
adsorption on the outer surface rather than encapsulation within pores (175,177). 
Accordingly, the use of larger meso-pore diameters to increase gene entrapment within 





3.6 Drug loading methods for mesoporous materials 
 
Various approaches have been used to load drugs into mesoporous matrices such as physical 
mixing, solvent based techniques, melt methods, supercritical fluids, microwave irradiation 
and co-spray drying. Physical mixing involves blending suitable amounts of drug and 
mesoporous materials until a uniform dispersion is obtained (138,178). The most employed 
approaches are solvent based techniques (solvent impregnation) which involves dissolving of 
drug in organic solvent followed by impregnation of the mesoporous material in a 
concentrated drug solution, followed by agitation of the mixture for several hours and solvent 
evaporation (90,120,130). The ‘incipient wetness procedure’ is an alternative solvent based 
technique which is achieved by several impregnation steps of the carrier in drug solution. 
Successive impregnations improve drug encapsulation significantly through complete pore 
filling (179). The melt technique is a simple and solvent-free process which is performed by 
melting the drug and the carrier together yielding a physical mixture at high temperatures 
(117,138), although drug stability and thermal properties are critical which could limit 
process applicability (180). 
The aforementioned ‘manual’ methods are only suitable where small quantities of 
encapsulated materials are required and are problematic on the industrial scales (180). In 
addition these conventional methods have intrinsic disadvantages such as the use of organic 
solvents that will require a subsequent solvent elimination process; impacting on time and 
cost factors (129). Therefore, supplementary approaches have been proposed to load drug 
into mesoporous carriers without affecting active stability such as supercritical fluids method 
(129,181), co-spray drying (182,183) and microwave irradiation (184). The supercritical fluid 
method (e.g. supercritical carbon dioxide) has yielded mesoporous materials with improved 
encapsulation properties. The supercritical fluid mediums liquid like density allows 
solubilisation of large quantities of drug and in tandem gas like diffusivity facilitates 
molecular access to the mesoporous matrix (129,181). Moreover, this process does not 
require solvent removal steps commonly associated with process involving organic solvents. 
Supercritical processing conditions, such as the pressure, can greatly affect drug loading into 
mesoporous silica, the drug solid state and resulting release profile. For instance, increasing 
the pressure can reduce drug loading efficiency. This process is a promising approach for 
loading poorly aqueous soluble drugs into silica mesoporous materials to improve their 
dissolution rate and oral bioavailability (129).  
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Another loading technique is co-spray drying of the drug with the mesoporous carrier. This 
approach involves dispersing the carrier in a solution of the drug in a volatile solvent 
followed by spray drying of the dispersion. Compared to solvent based techniques, this 
method produces more stable amorphous state of the drug with considerably enhanced 
dissolution rate and oral bioavailability (182,183). 
Microwave based methods have been explored to load drugs into mesoporous silica, which 
involves microwave irradiation of drug and MS mixture in a controlled temperature 
environment. This method avoids undesirable drug degradation as it ensures an ideal constant 
temperature throughout the process not exceeding critical values. In this method the drug 
melts inside silica pores in the amorphous form and resulting products have shown improved 
release properties (184). 
Surfactant assisted drug loading method (also termed one-pot synthesis) is a more recent 
approach when using mesoporous materials. In this method, drug is loaded during the 
synthesis of the mesoporous material, thus the drug is entrapped inside the surfactant micelle 
structure. This approach exploits the presence of the surfactant template as an adjuvant for 
loading the drug to increase its loading efficiency, enhance its release kinetic pattern and 
improve its stability. For example, loading levofloxacin using the surfactant assisted method 
increased the loading efficiency to 100% (145).   
 
3.7 Toxicity of mesoporous silica  
 
The current data on MSN toxicity is limited and controversial (185). However, MSNs are 
biocompatible materials at concentrations suitable for some pharmaceutical applications 
(185,186). The free surface silanol group in silica materials can interact and damage 
biomolecules such as cellular membrane proteins and lipids (187), and certain haemolytic 
activity has also been reported (188). However, most silanol groups in MSNs (unlike 
amorphous silica nanoparticles) are located in the internal surface of the particles and only a 
minor percentage of silanol groups are accessible to the bulk solution resulting in improved 
biocompatibility (188). Therefore, surface functionalisation of MS nanoparticles (MSNs) has 
the potential to decreases surface reactivity and enhancing their biocompatibility (187). 
MSNs exhibit higher biocompatibility than nonporous amorphous silica particles towards red 
blood cells. It was found that the intravenous administration of MSNs at concentrations up to 
100 μg/ml did not induce any haemolytic activity towards red blood cells (188). 
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With regards to tissue toxicity, intravenous administration of MSN into mice revealed no 
detectable histopathological abnormalities in spleen, liver, heart, kidney and lung. These 
findings suggest that MSNs do not cause tissue inflammation or toxicity. This could be 
attributed to stable physicochemical properties, biocompatibility of such particles and their 
degradation products (152). Moreover, Malvindi et al, conducted an in vitro cytotoxicity 
study using three different sizes of silica nanoparticles (25, 60 and 115 nm) and two surface 
charges (negative and positive) on five cell lines. The results showed no cytotoxic indications 
when using particle concentrations of up to 2.5 nM (on all cell lines). The cellular uptake of 
particles was mediated via endocytic process that is highly dependent on silica particle size 
and not the particle charge (189). Other studies have found that cytotoxicity of silica particles 
is highly dependent on particle size, concentration (148,190) and the presence of residual 
surfactant (148). For example, nano-sized MS particles demonstrated low cytotoxicity for 
concentrations up to 25 μg/ml whereas micron-sized particles showed slight cytotoxicity over 
a broad MS concentration up to 480 µg/ml. Subsequently, nano-sized particles are 
endocytosed more readily than micro-sized systems (148). However, a cytotoxicity study on 
MCM-41 and its functionalized analogs toward human neuroblastoma cells found these 
materials to be cytotoxic between concentrations of 40 to 800 μg/ml (191). Another research 
work performed on the effect of MCM-41 and SBA-15 nanoparticles on cellular respiration 
showed SBA-15 inhibited respiration rate, while MCM-41 had no detectable effect. The 
inhibition induced by SBA-15 nanoparticles was time and concentration dependant (192). 
Table 3 summarizes different toxicity studies performed on mesoporous silica particles. 
 
3.8 Future perspectives 
 
There are many physiological obstacles for the nano carriers preventing them from reaching 
to selective target sites, such as circulating from the blood to the tumor extracellular matrix, 
attaching to tumor-cell membrane for endocytosis, releasing the drug inside the cells and 
targeting the subcellular sites. Therefore, efforts have been devoted to design multifunctional 
nano carriers aims to overcome these physiological obstacles (193). Among different nano-
carriers, silica based nano-carriers are very attractive delivering the drug into selective sites 
(194), intracellular co-delivery of the drug and other therapeutic molecules such as genes 
(174) chemosensitisers (195) and peptides (193). 
Controlled release of the drug from MS materials can be achieved by adjusting their pore 
size, morphology and surface characteristics. However, these approaches results in ordinary 
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release profiles which cannot achieve the desired clinical outcomes (196). Therefore, it is 
essential to design responsive controlled delivery systems that can achieve a site targeted 
release that is triggered by intracellular or external stimuli (175). MSNs system (e.g. MSN 
and nanotubes) are interesting candidates capable of achieving stimuli responsive release 
(194,196,197). Responsive drug release from MS can be achieved by two main methods: 
covalent bonding of the drug to the silica via cleavable bonds or functionalisation of the outer 
surface of the MSN using removable coating or capping (gatekeepers) (175). In the later 
approach, pores loaded with the drug can be blocked by different gatekeepers which can 
prevent the carriers from releasing of the drug prematurely. The release of the encapsulated 
drug is triggered by certain stimuli that are capable of removing theses gatekeepers (194,198) 
and are classified into physical stimuli (e.g. temperature, light, electricity and magnetism) and 
chemical stimuli (enzymes, ionic strength and redox potential). However, the design of bio-
responsive systems that release drugs upon exposure to intracellular stimuli such as redox 
potential, enzymes and acidic pH are more valuable in biomedical applications (194,197). For 
instance, the pH responsive release system is an effective method for controlling drug release 
into selective sites (198). This is because of the pathological tissues which exhibit different 
pH from normal tissues, for example cancerous and inflammatory tissues have more acidic 
pH than normal tissues. For example, tannin functionalised MSNs were found to be potential 
carriers to design pH responsive drug delivery system for cancer and stomach treatment. 
Using tannin as a gatekeeper resulted in an efficient entrapment of the model drug inside the 
mesopores of MSN in the pH 7.4. By lowering the pH, tannin was cleaved rapidly with 
increasing the release of model drugs (142). Another interesting bio-responsive system is 
enzyme triggered strategy in which the enzymatic hydrolysis results in opening the coated 
mesopores and hence releasing the entrapped drug. An example for this system is 
demonstrated by lactose functionalised MS wherein a lactose derivative grafted on the 
surface of MS act as the gatekeeper (197).  
 
Multifunctional MSNs were utilised for intracellular co-delivery of therapeutic molecules 
with a great efficacy for enhancing the anticancer cytotoxicity and minimizing the multidrug 
resistance (156,157,193,195). Multidrug resistance (MDR) is the resistance of tumor cells to 
the chemotherapy where cancerous cells become resistant to different types of drugs 
simultaneously. MDR causes the most challenges for scientists to develop efficient 
chemotherapeutic treatment for the tumors (195). MDR is multifactorial and can be classified 
into two main mechanisms; pump resistance (caused by certain membrane-bound proteins 
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that form efflux pumps) and non-pump resistance (caused by activation of cellular anti-
apoptotic proteins). Thus it is important to inhibit these mechanisms simultaneously via 
targeting all of the intracellular molecular targets (156). A novel strategy to overcome the 
MDR can be achieved by co-delivery of the drug with nucleic acids (e.g. siRNA), wherein 
siRNA is capable of silencing genes responsible for MDR. MSNs have been reported to be 
successful systems for the delivery of anticancer drugs simultaneously with siRNA 
(156,157). The use of MSNs for simultaneous delivery of doxorubicin with siRNA into 
multidrug resistant ovarian cancerous cells enhanced the anticancer efficacy of doxorubicin. 
As this co-delivery system significantly inhibited the non-pump resistance mechanism, 
decreased the extracellular premature release of doxorubicin, delivered doxorubicin 
intracellularly into the perinuclear region and exerted synergistic cytotoxic effects to the 
cancerous cells. Functionalisation of MSNs with targeting moieties selective to cancerous 
cells will further enhance the anticancer efficiency of the system and decrease it’s adverse 
effects on normal cells (156). The co-delivery of the chemosenstiser with anticancer drug 
(paclitaxel) is able to supress the MDR of breast cancer cells and guarantee pH responsive 
release behaviour thus decreased adverse effects and toxicities to normal cells (195).  
 
3.9 Concluding Remarks 
 
Multifunctional MS based nano-carriers which possess unique features such as tunable pore 
size, high surface area, highly accessible free silanol groups, bioactivity and responsive 
release properties have significant potential in medical applications for enhancing clinical 
outcomes for a variety of drug delivery therapies. Though unconventional, such materials are 
a useful route to tailor drug delivery systems where polymeric materials may become 
problematic. The multi-variate design of drug delivery systems (associated with inorganic 
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2-5 nm Ordered two dimensional 
hexagonal arrangement of 
pores with  uni-directional 
channel 
Direct diffusion of loaded 
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channels 
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In vitro controlled 
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was achieved using 
SBA-15 as discs while 
the release rate was 
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administration forms of 
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The release of 
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Table 3.   A summary of selected toxicity studies performed on mesoporous silica particles. 
Silica type Concentration\ 
Dose 
Particle size Toxicity comments Ref. 
MCM-41- 
type MSN 
up to 100 μg/ml 100 and 
300nm 
No significant haemolytic 
activity was detected at a 
concentration of 100 μg/ml 
MSNs showed high 
biocompatibility at concentrations 





5 μl/g 80–360 nm Both types did not cause 
tissue toxicity. No 
noticeable histopathological 
abnormalities in spleen, 
liver, heart, kidney and 
lung. 
MSNs do not cause tissue 
inflammation or toxicity. This 
could be attributed to stable 
physicochemical properties, 
biocompatibility of such particles 
and their degradation products 
(152) 
MSN 50 mg/kg 110 nm MSN did not cause any 
changes in liver, spleen, 
kidney and lung 
morphology following  
exposure through different 
routes (at 50 mg/kg).  
Mesoporous silica are 
biocompatible when adminsterted 









10–480 μg/ml 190–1220 nm nano-sized MS particles 
demonstrated low 
cytotoxicity for 
concentrations up to 25 
μg/ml, whereas micron-
sized particles showed 
slight cytotoxicity over a 
broad MS concentration up 
to 480 µg/ml 
The cytotoxicity of silica particles 
was dependant on particle size  
(148) 








 SBA-15 supressed cellular 
respiration rate at 25–500 
µg/mL, while MCM-41 had 
no detectable effect on 
respiration rate. 
The cellular respiration inhibition 
of SBA-15 was concentration and 
time-dependent. The insignificant 
effect of MCM-41 is due to limited 
cellular uptake because of high 






40 to 800 µg/ml 250 nm MCM-41 and its 
functionalized analogues 
killed human cells under 
the test 
The highest cytoxicity is caused by 
MS with the largest surface area. 
However surface area is not the 
only factor contributing towards 
cytotoxicity. Other factors such as 
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